Harrow, Inc.

HROW ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-12.0M $-19.1M $-15.9M $-10.1M $-7.6M $-5.4M $-953.9K $-2.5M
Depreciation & Amortization $1.4M $1.1M $255.0K $37.0K — — — —
Depreciation $1.4M $1.1M $255.0K $37.0K $5.7K $2.9K $338 $1.1K
Amortization $364.0K $351.0K $355.0K $48.0K — — — —
Stock-Based Compensation $2.9M $3.7M $3.4M $2.6M $3.1M $2.2M $177.4K $680.2K
Net Cash from Operating Activities $-8.8M $-11.2M $-11.1M $-7.1M $-4.4M $-1.9M $-291.2K $-2.3M
Investing Activities
Capital Expenditures $772.0K $6.9M $-995.0K $174.0K $20.0K $15.5K $0 $0
Business Acquisitions — — $3.0M $636.4K — — — —
Net Cash from Investing Activities $-961.0K $-7.3M $-5.1M $-910.0K $-70.0K $-15.5K $0 $0
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — $-13.0K $191 — — —
Net Cash from Financing Activities $4.9M $24.7M $10.7M $599.0K $10.1M $11.8M $145.9K $1.0M
Net Change in Cash $-4.8M $6.2M $-5.5M $-7.4M $5.5M $9.9M $-145.3K $-1.3M
Free Cash Flow $-9.6M $-18.1M $-10.1M $-7.2M $-4.5M $-1.9M $-291.2K $-2.3M
← Newer Page 2 of 2 Older →